Edwards Lifesciences Corp (EW) stock
EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/3058% above fair value
$105.80−0.01 (-0.01%)
Close on Nov 12, 2026Market cap $60.98BP/E 59.8Yield –
Edwards Lifesciences r&d expenses
Research and development expenses are spending on new products and technology.
Edwards Lifesciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $1.09B, up 0.8% year over year. For fiscal 2025 it was $1.08B, up 2.5% from the year before. Over ten years it grew 10.9% a year on average. The highest annual figure on record is $1.08B in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.08B | +2.5% |
| FY2024 | Dec 31, 2024 | $1.05B | +9.4% |
| FY2023 | Dec 31, 2023 | $962.90M | +14.1% |
| FY2022 | Dec 31, 2022 | $843.60M | -6.6% |
| FY2021 | Dec 31, 2021 | $903.10M | +18.7% |
| FY2020 | Dec 31, 2020 | $760.70M | +1.1% |
| FY2019 | Dec 31, 2019 | $752.70M | +21.0% |
| FY2018 | Dec 31, 2018 | $622.20M | +12.6% |
| FY2017 | Dec 31, 2017 | $552.60M | +25.0% |
| FY2016 | Dec 31, 2016 | $442.20M | +15.5% |
| FY2015 | Dec 31, 2015 | $382.90M | +10.5% |
| FY2014 | Dec 31, 2014 | $346.50M | +7.3% |
| FY2013 | Dec 31, 2013 | $323.00M | +10.9% |
| FY2012 | Dec 31, 2012 | $291.30M | +18.3% |
| FY2011 | Dec 31, 2011 | $246.30M | +20.5% |
| FY2010 | Dec 31, 2010 | $204.40M | +16.5% |
| FY2009 | Dec 31, 2009 | $175.50M | +26.1% |
| FY2008 | Dec 31, 2008 | $139.20M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $281.40M | +0.2% |
| Q2 FY2026 | Jun 30, 2026 | $278.90M | +1.0% |
| Q1 FY2026 | Mar 31, 2026 | $263.30M | +3.4% |
| Q4 FY2025 | Dec 31, 2025 | $267.70M | -1.3% |
| Q3 FY2025 | Sep 30, 2025 | $280.70M | +10.8% |
| Q2 FY2025 | Jun 30, 2025 | $276.20M | +1.6% |
| Q1 FY2025 | Mar 31, 2025 | $254.60M | -0.8% |
| Q4 FY2024 | Dec 31, 2024 | $271.10M | +12.0% |
| Q3 FY2024 | Sep 30, 2024 | $253.40M | +4.4% |
| Q2 FY2024 | Jun 30, 2024 | $271.80M | +11.5% |
| Q1 FY2024 | Mar 31, 2024 | $256.70M | -1.7% |
| Q4 FY2023 | Dec 31, 2023 | $242.10M | +85.4% |
| Q3 FY2023 | Sep 30, 2023 | $242.80M | +3.9% |
| Q2 FY2023 | Jun 30, 2023 | $243.70M | -2.8% |
| Q1 FY2023 | Mar 31, 2023 | $261.20M | +14.3% |
| Q4 FY2022 | Dec 31, 2022 | $130.60M | -43.9% |
| Q3 FY2022 | Sep 30, 2022 | $233.60M | -1.8% |
| Q2 FY2022 | Jun 30, 2022 | $250.80M | +11.3% |
| Q1 FY2022 | Mar 31, 2022 | $228.60M | +10.4% |
| Q4 FY2021 | Dec 31, 2021 | $232.80M | +19.0% |
| Q3 FY2021 | Sep 30, 2021 | $238.00M | +21.7% |
| Q2 FY2021 | Jun 30, 2021 | $225.30M | +23.7% |
| Q1 FY2021 | Mar 31, 2021 | $207.00M | +10.5% |
| Q4 FY2020 | Dec 31, 2020 | $195.70M | +0.9% |
| Q3 FY2020 | Sep 30, 2020 | $195.50M | 0.0% |
| Q2 FY2020 | Jun 30, 2020 | $182.10M | -5.1% |
| Q1 FY2020 | Mar 31, 2020 | $187.40M | +9.3% |
| Q4 FY2019 | Dec 31, 2019 | $193.90M | +18.9% |
| Q3 FY2019 | Sep 30, 2019 | $195.50M | +20.8% |
| Q2 FY2019 | Jun 30, 2019 | $191.90M | +24.5% |
| Q1 FY2019 | Mar 31, 2019 | $171.40M | +19.7% |
| Q4 FY2018 | Dec 31, 2018 | $163.10M | +11.3% |
| Q3 FY2018 | Sep 30, 2018 | $161.80M | +13.2% |
| Q2 FY2018 | Jun 30, 2018 | $154.10M | +14.7% |
| Q1 FY2018 | Mar 31, 2018 | $143.20M | +11.3% |
| Q4 FY2017 | Dec 31, 2017 | $146.60M | +27.6% |
| Q3 FY2017 | Sep 30, 2017 | $142.90M | – |
| Q2 FY2017 | Jun 30, 2017 | $134.40M | – |
| Q1 FY2017 | Mar 31, 2017 | $128.70M | – |
| Q4 FY2016 | Dec 31, 2016 | $114.90M | – |
See a number that looks wrong?